VJHemOnc is committed to improving our service to you

ASH 2019 | Defibrotide in VOD/SOS after HSCT

VJHemOnc is committed to improving our service to you

Mohamad Mohty

Severe veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT). Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the first results from the prospective observational study (NCT03032016) performed by the European Society for Blood and Marrow Transplantation (EBMT). The goal of this registry was to collect safety and outcome data of defibrotide in patients diagnosed with VOD/SOS after HSCT. Prof. Mohty reveals defibrotide is active, not only in the therapy of VOD/SOS but also in prophylaxis. Additionally, results show a clear correlation between early initiation of treatment and efficacy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter